Orchid Pharma Ltd

AI
Orchid Pharma Summary Chart Analysis Peers Quarters Profit & Loss Balance Sheet Cash Flow Ratios Investors Documents
AI

Orchid Pharma Ltd

₹ 990 3.30%
18 Sep - close price
orchidpharma.com BSE: 524372 NSE: ORCHPHARMA
About

Orchid Pharma is a pharmaceutical company engaged in the development and manufacture of active pharmaceutical ingredients (APIs) and finished dosage forms. It is also engaged in research of new drugs. [1]

Key Points

Product Segments FY24
The company operates mainly in the Cephalosporins-based active pharmaceutical ingredients (API) business. These APIs are primarily used in anti-bacterial, anti-biotic, and anti-inflammatory formulations. [1][2]

Website BSE NSE
  • Market Cap ₹ 5,927 Cr.
  • Current Price ₹ 990
  • High / Low ₹ 1,133 / 471
  • Stock P/E 328
  • Book Value ₹ 300
  • Dividend Yield 0.00 %
  • ROCE 1.86 %
  • ROE 1.49 %
  • Face Value ₹ 10.0
Edit ratios

Pros

Cons

  • Stock is trading at 3.30 times its book value
  • Though the company is reporting repeated profits, it is not paying out dividend
  • Tax rate seems low
  • Company has a low return on equity of 6.76% over last 3 years.
  • Earnings include an other income of Rs.18.6 Cr.

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals

Part of BSE Healthcare BSE 1000

Edit Columns
Loading peers table ...

Quarterly Results

Consolidated Figures in Rs. Crores / View Standalone

Jun 2023 Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026 Jun 2026
182.92 198.76 220.59 217.10 244.41 222.70 217.34 237.48 263.19 193.52 207.27 368.33 304.17
160.78 175.46 185.21 188.19 211.92 192.36 190.97 209.49 268.84 194.99 205.71 338.17 290.17
Operating Profit 22.14 23.30 35.38 28.91 32.49 30.34 26.37 27.99 -5.65 -1.47 1.56 30.16 14.00
OPM % 12.10% 11.72% 16.04% 13.32% 13.29% 13.62% 12.13% 11.79% -2.15% -0.76% 0.75% 8.19% 4.60%
1.89 8.36 7.62 13.36 7.57 7.52 8.49 3.90 11.57 10.77 -1.50 7.55 1.83
Interest 5.55 3.80 3.54 3.47 3.50 3.33 3.80 3.92 2.28 3.73 3.18 1.96 2.23
Depreciation 7.71 7.84 9.27 8.42 8.44 8.63 8.61 8.87 10.53 8.90 9.03 10.90 10.95
Profit before tax 10.77 20.02 30.19 30.38 28.12 25.90 22.45 19.10 -6.89 -3.33 -12.15 24.85 2.65
Tax % 0.00% 0.00% 0.00% -10.27% -0.53% 0.00% 0.00% -0.21% 0.00% 0.00% 0.00% 0.00% 2.64%
9.40 19.80 29.43 32.96 29.35 27.24 20.78 22.29 -5.69 -5.72 -12.61 25.84 3.22
EPS in Rs 1.85 3.90 5.80 6.50 5.79 5.37 4.10 4.39 -1.12 -1.13 -2.49 5.09 0.63
Raw PDF

Profit & Loss

Consolidated Figures in Rs. Crores / View Standalone

Mar 2015 18m Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026 TTM
1,747 873 797 683 600 484 450 560 666 819 1,398 1,233 1,073
1,429 703 794 659 612 515 421 505 581 708 1,247 1,185 1,029
Operating Profit 317 171 3 24 -12 -31 29 55 84 111 151 48 44
OPM % 18% 20% 0.4% 3.6% -2.0% -6% 7% 10% 13% 14% 11% 3.9% 4.1%
156 -28 -59 20 218 24 15 67 52 31 26 15 19
Interest 537 294 347 310 7 6 52 33 33 17 13 9 11
Depreciation 325 145 141 133 130 118 109 87 55 33 42 43 40
Profit before tax -389 -296 -544 -399 69 -131 -117 2 48 92 122 10 12
Tax % -49% -6% -9% -12% 0% 0% 0% 0% 0% -3% -8% -2%
-197 -279 -495 -353 69 -131 -117 -2 46 92 135 10 11
EPS in Rs -23.06 -31.37 -55.69 -39.65 7.80 -32.11 -28.55 -0.48 11.35 18.17 26.63 1.96 2.10
Dividend Payout % 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0%
Compounded Sales Growth
10 Years: 4%
5 Years: 22%
3 Years: 23%
TTM: 14%
Compounded Profit Growth
10 Years: 8%
5 Years: 17%
3 Years: 53%
TTM: -72%
Stock Price CAGR
10 Years: 38%
5 Years: 19%
3 Years: 24%
1 Year: 26%
Return on Equity
10 Years: %
5 Years: 5%
3 Years: 7%
Last Year: 1%

Balance Sheet

Consolidated Figures in Rs. Crores / View Standalone

Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Equity Capital 85 89 89 89 89 41 41 41 41 51 15 15
Reserves 244 -40 -556 -881 -793 725 612 607 648 1,119 1,494 1,504
3,211 3,215 3,106 3,202 3,230 566 453 268 331 135 154 307
521 598 616 715 551 128 132 195 205 249 414 432
Total Liabilities 4,061 3,862 3,256 3,125 3,077 1,460 1,237 1,111 1,225 1,554 2,077 2,258
1,795 1,637 1,497 1,386 1,256 858 670 584 573 620 708 692
CWIP 282 280 288 272 278 26 7 10 46 31 81 414
Investments 1 1 1 1 0 0 15 45 44 46 60 67
1,984 1,944 1,470 1,467 1,542 576 544 472 561 857 1,229 1,086
Total Assets 4,061 3,862 3,256 3,125 3,077 1,460 1,237 1,111 1,225 1,554 2,077 2,258

Cash Flows

Consolidated Figures in Rs. Crores / View Standalone

Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
-369 212 401 9 12 81 24 92 18 126 51 126
1,334 -1 -176 -28 45 167 67 113 -31 -312 -36 -277
-597 -286 -465 33 -0 -250 -165 -217 31 167 2 137
Net Cash Flow 367 -76 -240 15 57 -2 -74 -11 18 -19 17 -14
Free Cash Flow 965 211 392 3 5 77 23 238 -8 61 -102 -255
CFO/OP -102% 124% 13,628% 67% -138% -226% 63% 173% 22% 113% 44% 259%

Ratios

Consolidated Figures in Rs. Crores / View Standalone

Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Debtor Days 54 130 75 64 73 51 110 111 118 87 92 113
Inventory Days 118 220 196 202 214 254 244 201 217 199 187 161
Days Payable 146 341 402 374 381 182 176 195 165 173 137 150
Cash Conversion Cycle 26 9 -130 -108 -94 123 179 117 170 113 142 124
Working Capital Days -49 -168 -500 -876 -1,158 166 302 97 54 118 101 105
ROCE % 1% 1% -4% -4% -5% -6% -5% -2% 5% 9% 9% 2%

Insights

In beta
Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Exports as % of Total Revenue (FOB / Turnover)
% ・Standalone data

Log in to view insights

Please log in to see hidden values.

Login
R&D Spend as % of Total Turnover
% ・Standalone data
Permanent Employees on Rolls
count ・Standalone data
Cumulative US ANDA Approvals
count
Cumulative US DMF Filings
count
Oral API Sales Volume
MT ・Standalone data
Sterile API Sales Volume
MT ・Standalone data
Regulated Markets Share of Revenue
%
R&D Expenditure (Percentage of Turnover)
% ・Standalone data

Extracted by Screener AI

Shareholding Pattern

Numbers in percentages

Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
72.40% 69.84% 69.84% 69.84% 69.84% 69.84% 69.84% 69.84% 69.84% 69.84% 69.84% 69.84%
8.08% 4.14% 1.96% 1.42% 1.94% 2.53% 2.69% 1.39% 1.56% 1.17% 0.87% 0.80%
12.46% 14.51% 17.73% 18.93% 18.30% 19.00% 20.10% 19.43% 19.04% 19.38% 20.24% 20.75%
7.05% 11.52% 10.47% 9.82% 9.94% 8.63% 7.37% 9.34% 9.57% 9.61% 9.04% 8.62%
No. of Shareholders 29,19736,93136,72034,69536,36334,15834,30339,82738,15535,70935,11833,433

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Announcements

Annual reports

Credit ratings

Concalls